Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179547 | 0.83 | IDO1 (0.44) | IDO1MPORIPK1AGXTLOXL2 | |
| SCHEMBL27667516 | 0.79 | IDO1 (0.36) | IDO1MPORIPK1SLC6A2SLC6A4 | |
| SCHEMBL109671 | 0.77 | IDO1 (0.65) | IDO1MPOAGXTLOXL2SLC6A2 | |
| SCHEMBL19413082 | 0.77 | RIPK1 (0.41) | IDO1RIPK1NR3C1NR3C2 | |
| SCHEMBL27576203 | 0.77 | IDO1 (0.35) | IDO1MPORIPK1NR3C1NR3C2 | |
| SCHEMBL27594514 | 0.76 | IDO1 (0.39) | IDO1MPORIPK1AGXTLOXL2 | |
| SCHEMBL27576202 | 0.76 | IDO1 (0.39) | IDO1MPOAGXTLOXL2NR3C1 | |
| SCHEMBL23964558 | 0.74 | NR3C1 (0.43) | RIPK1NR3C1NR3C2PGR | |
| SCHEMBL28113513 | 0.74 | RIPK1 (0.33) | IDO1RIPK1NR3C1NR3C2 | |
| SCHEMBL23612388 | 0.73 | PNMT (0.45) | IDO1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | IDO1 3086/4885MPO 1791/4885RIPK1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.